Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

p53-Regulated Long Noncoding RNA PRECSIT Promotes Progression of Cutaneous Squamous Cell Carcinoma via STAT3 Signaling.

Piipponen M, Nissinen L, Riihilä P, Farshchian M, Kallajoki M, Peltonen J, Peltonen S, Kähäri VM.

Am J Pathol. 2020 Feb;190(2):503-517. doi: 10.1016/j.ajpath.2019.10.019. Epub 2019 Dec 12.

2.

Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials).

Perez IM, Jambor I, Kauko T, Verho J, Ettala O, Falagario U, Merisaari H, Kiviniemi A, Taimen P, Syvänen KT, Knaapila J, Seppänen M, Rannikko A, Riikonen J, Kallajoki M, Mirtti T, Lamminen T, Saunavaara J, Pahikkala T, Boström PJ, Aronen HJ.

J Magn Reson Imaging. 2019 Nov 21. doi: 10.1002/jmri.26975. [Epub ahead of print]

PMID:
31750988
3.

Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machine-Learning Techniques.

Montoya Perez I, Jambor I, Pahikkala T, Airola A, Merisaari H, Saunavaara J, Alinezhad S, Väänänen RM, Tallgrén T, Verho J, Kiviniemi A, Ettala O, Knaapila J, Syvänen KT, Kallajoki M, Vainio P, Aronen HJ, Pettersson K, Boström PJ, Taimen P.

J Magn Reson Imaging. 2019 Oct 6. doi: 10.1002/jmri.26945. [Epub ahead of print]

PMID:
31588660
4.

Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.

Haddad BR, Erickson A, Udhane V, LaViolette PS, Rone JD, Kallajoki MA, See WA, Rannikko A, Mirtti T, Nevalainen MT.

Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1642-1651. doi: 10.1158/1055-9965.EPI-18-1358. Epub 2019 Jul 10.

5.

Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.

Jambor I, Verho J, Ettala O, Knaapila J, Taimen P, Syvänen KT, Kiviniemi A, Kähkönen E, Perez IM, Seppänen M, Rannikko A, Oksanen O, Riikonen J, Vimpeli SM, Kauko T, Merisaari H, Kallajoki M, Mirtti T, Lamminen T, Saunavaara J, Aronen HJ, Boström PJ.

PLoS Med. 2019 Jun 3;16(6):e1002813. doi: 10.1371/journal.pmed.1002813. eCollection 2019 Jun.

6.

Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma.

Riihilä P, Viiklepp K, Nissinen L, Farshchian M, Kallajoki M, Kivisaari A, Meri S, Peltonen J, Peltonen S, Kähäri VM.

Br J Dermatol. 2020 Mar;182(3):658-670. doi: 10.1111/bjd.18095. Epub 2019 Jul 28.

7.

ANO7 is associated with aggressive prostate cancer.

Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, Pursiheimo JP, Tammela T, Kellokumpu-Lehtinen PL; PRACTICAL Consortium, Fey V, Maehle L, Wiklund F, Wei GH, Schleutker J.

Int J Cancer. 2018 Nov 15;143(10):2479-2487. doi: 10.1002/ijc.31746. Epub 2018 Sep 22.

8.

New prostate cancer grade grouping system predicts survival after radical prostatectomy.

Erickson A, Sandeman K, Lahdensuo K, Nordling S, Kallajoki M, Seikkula H, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T.

Hum Pathol. 2018 May;75:159-166. doi: 10.1016/j.humpath.2018.01.027. Epub 2018 Feb 13. No abstract available.

9.

Intensity of 18F-FDG PET Uptake in Culture-Negative and Culture-Positive Cases of Chronic Osteomyelitis.

Lankinen P, Seppänen M, Mattila K, Kallajoki M, Knuuti J, Aro HT.

Contrast Media Mol Imaging. 2017 Oct 11;2017:9754293. doi: 10.1155/2017/9754293. eCollection 2017.

10.

Tumor cell-specific AIM2 regulates growth and invasion of cutaneous squamous cell carcinoma.

Farshchian M, Nissinen L, Siljamäki E, Riihilä P, Piipponen M, Kivisaari A, Kallajoki M, Grénman R, Peltonen J, Peltonen S, Quint KD, Bavinck JNB, Kähäri VM.

Oncotarget. 2017 Jul 11;8(28):45825-45836. doi: 10.18632/oncotarget.17573.

11.

Complement Component C3 and Complement Factor B Promote Growth of Cutaneous Squamous Cell Carcinoma.

Riihilä P, Nissinen L, Farshchian M, Kallajoki M, Kivisaari A, Meri S, Grénman R, Peltonen S, Peltonen J, Pihlajaniemi T, Heljasvaara R, Kähäri VM.

Am J Pathol. 2017 May;187(5):1186-1197. doi: 10.1016/j.ajpath.2017.01.006. Epub 2017 Mar 17.

12.

Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial).

Jambor I, Boström PJ, Taimen P, Syvänen K, Kähkönen E, Kallajoki M, Perez IM, Kauko T, Matomäki J, Ettala O, Merisaari H, Kiviniemi A, Dean PB, Aronen HJ.

J Magn Reson Imaging. 2017 Oct;46(4):1089-1095. doi: 10.1002/jmri.25641. Epub 2017 Feb 6.

PMID:
28165653
13.

Expression of claudin-11 by tumor cells in cutaneous squamous cell carcinoma is dependent on the activity of p38δ.

Nissinen L, Siljamäki E, Riihilä P, Piipponen M, Farshchian M, Kivisaari A, Kallajoki M, Raiko L, Peltonen J, Peltonen S, Kähäri VM.

Exp Dermatol. 2017 Sep;26(9):771-777. doi: 10.1111/exd.13278. Epub 2017 Apr 10.

PMID:
27992079
14.

Long Noncoding RNA PICSAR Promotes Growth of Cutaneous Squamous Cell Carcinoma by Regulating ERK1/2 Activity.

Piipponen M, Nissinen L, Farshchian M, Riihilä P, Kivisaari A, Kallajoki M, Peltonen J, Peltonen S, Kähäri VM.

J Invest Dermatol. 2016 Aug;136(8):1701-1710. doi: 10.1016/j.jid.2016.03.028. Epub 2016 Apr 2.

15.

Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.

Yu L, Toriseva M, Tuomala M, Seikkula H, Elo T, Tuomela J, Kallajoki M, Mirtti T, Taimen P, Boström PJ, Alanen K, Nurmi M, Nees M, Härkönen P.

Int J Cancer. 2016 Jul 1;139(1):140-52. doi: 10.1002/ijc.30048. Epub 2016 Mar 12.

16.

Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.

Alinezhad S, Väänänen RM, Tallgrén T, Perez IM, Jambor I, Aronen H, Kähkönen E, Ettala O, Syvänen K, Nees M, Kallajoki M, Taimen P, Boström PJ, Pettersson K.

Urol Oncol. 2016 Jun;34(6):255.e15-22. doi: 10.1016/j.urolonc.2015.12.014. Epub 2016 Feb 5.

PMID:
26857646
17.

[Diagnosis of soft tissue tumors--multidisciplinary collaboration].

Söderström M, Dalin-Hirvonen N, Mattila K, Knuutila S, Kallajoki M.

Duodecim. 2015;131(8):769-80. Finnish.

PMID:
26237892
18.

EphB2 Promotes Progression of Cutaneous Squamous Cell Carcinoma.

Farshchian M, Nissinen L, Siljamäki E, Riihilä P, Toriseva M, Kivisaari A, Ala-Aho R, Kallajoki M, Veräjänkorva E, Honkanen HK, Heljasvaara R, Pihlajaniemi T, Grénman R, Peltonen J, Peltonen S, Kähäri VM.

J Invest Dermatol. 2015 Jul;135(7):1882-1892. doi: 10.1038/jid.2015.104. Epub 2015 Mar 19.

19.

Complement factor I promotes progression of cutaneous squamous cell carcinoma.

Riihilä P, Nissinen L, Farshchian M, Kivisaari A, Ala-Aho R, Kallajoki M, Grénman R, Meri S, Peltonen S, Peltonen J, Kähäri VM.

J Invest Dermatol. 2015 Feb;135(2):579-588. doi: 10.1038/jid.2014.376. Epub 2014 Sep 3.

20.

Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma.

Riihilä PM, Nissinen LM, Ala-Aho R, Kallajoki M, Grénman R, Meri S, Peltonen S, Peltonen J, Kähäri VM.

J Invest Dermatol. 2014 Feb;134(2):498-506. doi: 10.1038/jid.2013.346. Epub 2013 Aug 12.

21.

In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548.

Kähkönen E, Jambor I, Kemppainen J, Lehtiö K, Grönroos TJ, Kuisma A, Luoto P, Sipilä HJ, Tolvanen T, Alanen K, Silén J, Kallajoki M, Roivainen A, Schäfer N, Schibli R, Dragic M, Johayem A, Valencia R, Borkowski S, Minn H.

Clin Cancer Res. 2013 Oct 1;19(19):5434-43. doi: 10.1158/1078-0432.CCR-12-3490. Epub 2013 Aug 9.

22.

Unusual case of inflammatory myofibroblastic tumor in maxilla.

Rautava J, Soukka T, Peltonen E, Nurmenniemi P, Kallajoki M, Syrjänen S.

Case Rep Dent. 2013;2013:876503. doi: 10.1155/2013/876503. Epub 2013 Apr 16.

23.

Characterization of hepatic tumors using [11C]metomidate through positron emission tomography: comparison with [11C]acetate.

Roivainen A, Naum A, Nuutinen H, Leino R, Nurmi H, Någren K, Parkkola R, Virtanen J, Kallajoki M, Kujari H, Ovaska J, Roberts P, Seppänen M.

EJNMMI Res. 2013 Feb 27;3(1):13. doi: 10.1186/2191-219X-3-13.

24.

[Mesenterial fibrosis--could it be desmoidi?].

Auranen A, Kallajoki M, Lavonius M, Lindholm P.

Duodecim. 2012;128(24):2562-8. Review. Finnish.

PMID:
23393930
25.

Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma.

Nordberg J, Mpindi JP, Iljin K, Pulliainen AT, Kallajoki M, Kallioniemi O, Elenius K, Elenius V.

PLoS One. 2012;7(12):e50819. doi: 10.1371/journal.pone.0050819. Epub 2012 Dec 5.

26.

Ewing's sarcoma family of tumors in Finland during 1990-2009: a population-based study.

Serlo JA, Helenius IJ, Sampo M, Vettenranta K, Saarinen-Pihkala UM, Kivivuori SM, Riikonen P, Kivioja A, Böhling T, Kallajoki M, Ristimäki A, Vasama K, Tarkkanen M.

Acta Oncol. 2013 May;52(4):767-75. doi: 10.3109/0284186X.2012.728714. Epub 2012 Nov 22.

PMID:
23173760
27.

Melanoma-associated cancer-testis antigen 16 (CT16) regulates the expression of apoptotic and antiapoptotic genes and promotes cell survival.

Nylund C, Rappu P, Pakula E, Heino A, Laato L, Elo LL, Vihinen P, Pyrhönen S, Owen GR, Larjava H, Kallajoki M, Heino J.

PLoS One. 2012;7(9):e45382. doi: 10.1371/journal.pone.0045382. Epub 2012 Sep 21.

28.

c-Jun N-terminal kinase phosphorylation of MARCKSL1 determines actin stability and migration in neurons and in cancer cells.

Björkblom B, Padzik A, Mohammad H, Westerlund N, Komulainen E, Hollos P, Parviainen L, Papageorgiou AC, Iljin K, Kallioniemi O, Kallajoki M, Courtney MJ, Mågård M, James P, Coffey ET.

Mol Cell Biol. 2012 Sep;32(17):3513-26. doi: 10.1128/MCB.00713-12. Epub 2012 Jul 2.

29.

CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice.

Ventelä S, Côme C, Mäkelä JA, Hobbs RM, Mannermaa L, Kallajoki M, Chan EK, Pandolfi PP, Toppari J, Westermarck J.

PLoS One. 2012;7(3):e33209. doi: 10.1371/journal.pone.0033209. Epub 2012 Mar 26.

30.

Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma.

Farshchian M, Kivisaari A, Ala-Aho R, Riihilä P, Kallajoki M, Grénman R, Peltonen J, Pihlajaniemi T, Heljasvaara R, Kähäri VM.

Am J Pathol. 2011 Sep;179(3):1110-9. doi: 10.1016/j.ajpath.2011.05.012. Epub 2011 Jul 1.

31.

PET imaging of blood flow and glucose metabolism in localized musculoskeletal tumors of the extremities.

Lindholm P, Sutinen E, Oikonen V, Mattila K, Tarkkanen M, Kallajoki M, Aro H, Böhling T, Kivioja A, Elomaa I, Minn H.

Nucl Med Biol. 2011 Feb;38(2):295-300. doi: 10.1016/j.nucmedbio.2010.08.012. Epub 2010 Oct 27.

PMID:
21315286
32.

Detection of melanoma-derived cancer-testis antigen CT16 in patient sera by a novel immunoassay.

Rappu P, Nylund C, Ristiniemi N, Kulpakko J, Vihinen P, Hernberg M, Mirtti T, Alanen K, Kallajoki M, Vuoristo MS, Pyrhönen S, Heino J.

Int J Cancer. 2011 May 15;128(10):2382-92. doi: 10.1002/ijc.25571.

33.

Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma.

Kivisaari AK, Kallajoki M, Ala-aho R, McGrath JA, Bauer JW, Königová R, Medvecz M, Beckert W, Grénman R, Kähäri VM.

Br J Dermatol. 2010 Oct;163(4):726-35. doi: 10.1111/j.1365-2133.2010.09924.x. Epub 2010 Sep 2.

PMID:
20586780
34.

Silencing of Nuclear Mitotic Apparatus protein (NuMA) accelerates the apoptotic disintegration of the nucleus.

Kivinen K, Taimen P, Kallajoki M.

Apoptosis. 2010 Aug;15(8):936-45. doi: 10.1007/s10495-010-0506-8.

PMID:
20467816
35.

Effect of childhood acute lymphoblastic leukemia therapy on spermatogonia populations and future fertility.

Nurmio M, Keros V, Lähteenmäki P, Salmi T, Kallajoki M, Jahnukainen K.

J Clin Endocrinol Metab. 2009 Jun;94(6):2119-22. doi: 10.1210/jc.2009-0060. Epub 2009 Mar 24.

PMID:
19318447
36.

Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.

Mirtti T, Laine VJ, Hiekkanen H, Hurme S, Rowe O, Nevalainen TJ, Kallajoki M, Alanen K.

APMIS. 2009 Mar;117(3):151-61. doi: 10.1111/j.1600-0463.2008.00002.x.

PMID:
19245588
37.

Histopathological evidence for an association of inflammation with ductal pin-like lesions but not with ductal adenocarcinoma in the prostate of the noble rat.

Bernoulli J, Yatkin E, Laakso A, Anttinen M, Bosland M, Vega K, Kallajoki M, Santti R, Pylkkänen L.

Prostate. 2008 May 15;68(7):728-39. doi: 10.1002/pros.20719.

PMID:
18302197
38.

Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas.

Kivisaari AK, Kallajoki M, Mirtti T, McGrath JA, Bauer JW, Weber F, Königová R, Sawamura D, Sato-Matsumura KC, Shimizu H, Csikós M, Sinemus K, Beckert W, Kähäri VM.

Br J Dermatol. 2008 Apr;158(4):778-85. doi: 10.1111/j.1365-2133.2008.08466.x. Epub 2008 Feb 16.

PMID:
18284387
39.

p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells.

Junttila MR, Ala-Aho R, Jokilehto T, Peltonen J, Kallajoki M, Grenman R, Jaakkola P, Westermarck J, Kähäri VM.

Oncogene. 2007 Aug 9;26(36):5267-79. Epub 2007 Mar 5.

PMID:
17334397
40.

Cardiomyocyte apoptosis and duration of aortic clamping in pig model of open heart surgery.

Malmberg M, Vähäsilta T, Saraste A, Kytö V, Kiss J, Kentala E, Kallajoki M, Savunen T.

Eur J Cardiothorac Surg. 2006 Sep;30(3):480-4. Epub 2006 Jul 20.

PMID:
16859918
41.

Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.

Vähä-Koskela MJ, Kallio JP, Jansson LC, Heikkilä JE, Zakhartchenko VA, Kallajoki MA, Kähäri VM, Hinkkanen AE.

Cancer Res. 2006 Jul 15;66(14):7185-94.

42.

Cardiomyocyte apoptosis after antegrade and retrograde cardioplegia.

Vähäsilta T, Saraste A, Kytö V, Malmberg M, Kiss J, Kentala E, Kallajoki M, Savunen T.

Ann Thorac Surg. 2005 Dec;80(6):2229-34.

PMID:
16305878
43.

Caspase-3 is required in the apoptotic disintegration of the nuclear matrix.

Kivinen K, Kallajoki M, Taimen P.

Exp Cell Res. 2005 Nov 15;311(1):62-73. Epub 2005 Sep 30.

PMID:
16199031
44.

Regulation of prostate cell collagen receptors by malignant transformation.

Mirtti T, Nylund C, Lehtonen J, Hiekkanen H, Nissinen L, Kallajoki M, Alanen K, Gullberg D, Heino J.

Int J Cancer. 2006 Feb 15;118(4):889-98.

45.

NuMA in rat testis--evidence for roles in proliferative activity and meiotic cell division.

Taimen P, Parvinen M, Osborn M, Kallajoki M.

Exp Cell Res. 2004 Aug 15;298(2):512-20.

PMID:
15265698
46.

[Nuclear lamins and their diseases].

Taimen P, Kalimo H, Kallajoki M.

Duodecim. 2004;120(7):799-805. Review. Finnish. No abstract available.

PMID:
15154299
47.

Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo.

Ala-aho R, Ahonen M, George SJ, Heikkilä J, Grénman R, Kallajoki M, Kähäri VM.

Oncogene. 2004 Jul 1;23(30):5111-23.

PMID:
15094779
48.

Altered expression of syndecan-1 in prostate cancer.

Kiviniemi J, Kallajoki M, Kujala I, Matikainen MT, Alanen K, Jalkanen M, Salmivirta M.

APMIS. 2004 Feb;112(2):89-97.

PMID:
15056224
50.

Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course.

Lasota J, Dansonka-Mieszkowska A, Stachura T, Schneider-Stock R, Kallajoki M, Steigen SE, Sarlomo-Rikala M, Boltze C, Kordek R, Roessner A, Stachura J, Miettinen M.

Mod Pathol. 2003 Dec;16(12):1257-64.

Supplemental Content

Loading ...
Support Center